Exabis Library
Welcome to the e-CCO Library!
DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP35: Increasing incidence of pouchitis among patients undergoing ileal pouch-anal anastomosis between 1996 and 2018: A population-based Danish cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s disease, is significantly amplified in patients with a complicated phenotype
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP35: Monitoring of mucosal T cells subsets under biotherapies in IBD: Responders exhibit a phenotype similar to healthy controls
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP35: Spatial transcriptomics reveals cellular niches associated with histological inflammation in postoperative Crohn’s Disease
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP36 Family-specific host genetic and gut microbial signatures have a beneficial role in early identification of familial inflammatory bowel diseases
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP36: Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP36: Gut microbial variations in patients with quiescent Crohn’s disease predict subsequent disease flare
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP36: Gut microbial variations in patients with quiescent Crohns disease predict subsequent disease flare
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP36: Non-invasive assessment of postoperative disease recurrence in Crohn’s Disease: A multicenter, prospective cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signature
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signature
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP37 Neoplastic lesions outside diseased area in inflammatory bowel disease patients: A national cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP37: Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP37: Large differences in IBD care and education across Europe, first results of the pan-European VIPER survey
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP37: Neoplastic lesions outside diseased area in Inflammatory Bowel Disease patients: A National Cohort Study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP37: Neoplastic lesions outside diseased area in Inflammatory Bowel Disease patients: A National Cohort Study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1